U.S. markets open in 1 hour 24 minutes

GW Pharmaceuticals plc (GWPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
96.35+0.28 (+0.29%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close96.07
Open96.36
Bid94.63 x 1000
Ask0.00 x 900
Day's Range95.04 - 96.85
52 Week Range67.98 - 141.98
Volume174,898
Avg. Volume378,550
Market Cap2.934B
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-1.78
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est190.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community
    GlobeNewswire

    Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

    Riley's Family Using UnspokenSymphony.com Riley’s family watching her artwork change to music on UnspokenSymphony.com\-- Technology provides a new way for the community to communicate and connect \--\-- Launching in collaboration with patient advocacy organizations, this web-based, image-recognition technology bridges music and art to provide a voice for those who struggle to express themselves \--CARLSBAD, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Greenwich Biosciences, Inc., the US leader in the field of cannabinoid prescription medicines and subsidiary of GW Pharmaceuticals plc (Nasdaq: GWPH), today announced the launch of unspoken symphony, a web-based, image-recognition technology that gives individuals with epilepsy who struggle to express themselves verbally a new way to communicate and connect like never before by translating artwork into a melody. Many people living with epilepsy may experience developmental delays or cognitive impairment in addition to seizures, making it challenging to verbalize or connect with others. This is particularly common in seizure conditions such as Lennox-Gastaut syndrome (LGS), Dravet syndrome and tuberous sclerosis complex (TSC).i,ii Often, individuals with limited verbal ability turn to art and/or music therapy as a way to express themselves. unspoken symphony offers a unique way to bridge the two.unspoken symphony was inspired by a girl named Riley, 15, who is living with LGS and TSC. While she has never been able to speak, she was able to express herself through painting. From this, Greenwich Biosciences was inspired to develop a way for Riley, and the US epilepsy community, to translate their art into an expression of sound, line by line, note by note.“It’s not easy getting to know someone who can’t talk,” said Riley’s dad, Tim. “In fact, I think one of the biggest challenges caregivers can face is connecting with a child who struggles to express themselves. The ability to connect with Riley through her artwork has been amazing. We are proud to be a part of unspoken symphony and excited that families like ours will have the opportunity to connect in a new way.”The unspoken symphony website allows visitors to upload artwork created with any medium (e.g., drawing, painting, computer-generated) using a mobile device or scanner. Using a breakthrough image-recognition technology, the art is analyzed and translated into a melody within seconds, converting each piece of artwork into its own unique musical expression. Users can create and play their melodies within the website, and also receive a printable version of their artwork in the form of sheet music, as well as an animated video file of the notes being played on top of their artwork. These items can be saved and shared with family, friends and via social media channels. In addition to allowing visitors to submit artwork to be turned into a melody, the website’s gallery features the unspoken symphonies of those living with LGS, Dravet syndrome and TSC.“As a company, patients are at the center of everything we do and we strive to deliver innovation that goes beyond medicine to offer novel ways to help the communities we serve,” said Justin Gover, Greenwich Biosciences’ Chief Executive Officer. “We were inspired to create unspoken symphony for all who struggle to express themselves. When we first met Riley’s parents, they told us how difficult it can be to get to know someone who can’t speak. It’s a heartbreaking challenge and we – in collaboration with our advocacy partners – are proud to bring this technology to those looking for a new way to communicate and connect with loved ones in a way that was not possible before.”Greenwich Biosciences is launching unspoken symphony in collaboration with the Dravet Syndrome Foundation, the Epilepsy Foundation, the Lennox-Gastaut Foundation and the Tuberous Sclerosis Alliance. To learn more, visit www.unspokensymphony.com.About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company is also carrying out a Phase 3 trial in Rett syndrome and has a deep pipeline of additional cannabinoid product candidates, including nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.Enquiries:GW Pharmaceuticals plc  Stephen Schultz, VP Investor Relations (U.S.)917 280 2424 / 401 500 6570    U.S. Media Enquiries: Sam Brown Inc. Healthcare Communications   Christy Curran Mike Beyer615 414 8668 312 961 2502   1. Greenwich Biosciences. Beyond Seizures: Comorbid Clinical Features and Multidisciplinary Management of Lennox-Gastaut Syndrome and Dravet Syndrome. Available at https://www.greenwichbiosciences.com/sites/default/files/pdf/comorbidity-lgs-dravet-syndrome.pdf. Accessed August 20, 2020. 2. Tuberous Sclerosis Alliance. TSC and Autism Spectrum Disorders. Available at: https://www.tsalliance.org/about-tsc/signs-and-symptoms-of-tsc/brain-and-neurological-function/tsc-and-autism-spectrum-disorders/. Accessed August 20, 2020. A photo accompanying this announcement is available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/b27a0234-2a52-4716-af62-7a75c49f2821Videos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/ef49f8ff-4d0e-42e3-a6d4-01e3b245bbcahttps://www.globenewswire.com/NewsRoom/AttachmentNg/f0338885-3873-453f-85c0-5f2ec7d4545cDocuments accompanying this announcement are available at:http://ml.globenewswire.com/Resource/Download/5abbcf4c-d6c0-48a3-adce-78ea020764afhttp://ml.globenewswire.com/Resource/Download/cf0da277-c808-4179-bb21-c90e2e7c236f

  • Hedge Funds Are Getting Out Of GW Pharmaceuticals plc (GWPH)
    Insider Monkey

    Hedge Funds Are Getting Out Of GW Pharmaceuticals plc (GWPH)

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]

  • 3 Marijuana Stocks to Buy With Decriminalization on the Table
    InvestorPlace

    3 Marijuana Stocks to Buy With Decriminalization on the Table

    In late September, a U.S. House vote to remove marijuana from the federal Controlled Substances Act was delayed until after the presidential election. If the House remains controlled by Democrats, industry analysts expect the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to potentially pass before the end of 2020. Then, it would be up to the Senate to possibly take a similar action. Today, we will look at three marijuana stocks to buy with decriminalization in the agenda. Canada is the first and only G7 nation to have legalized cannabis nationwide. In the U.S., at the federal level, marijuana is illegal and remains a Schedule I drug. Legal status varies at the state level. However, Democratic vice president nominee Kamala Harris has recently said marijuana would be decriminalized at the federal level under a Biden administration. 2018 saw excessive speculation in marijuana stocks. Yet since 2019, a wide range of issues have affected the cannabis industry. Recreational cannabis sales in Canada hit significant headwinds and never reached the levels investors hoped. Although revenue improved for some companies, they have yet to become profitable. And cash burn remains concerning. As a result, most marijuana stocks have been on a roller coaster ride and hit new lows. Put another way, the bubble has burst.InvestorPlace - Stock Market News, Stock Advice & Trading Tips According to recent research led by Douglas Berman of Ohio State University, “the COVID-19 pandemic has both introduced tremendous new challenges for the cannabis industry and exacerbated long-standing difficulties for businesses in this arena.” 7 Value Stocks to Buy in an Overvalued Market Nonetheless, with difficulties usually come new opportunities while industry leaders and innovations may appear. With that information, here are three marijuana stocks that could benefit from U.S. developments at the federal level: Constellation Brands (NYSE:STZ) ETFMG Alternative Harvest ETF (NYSEARCA:MJ) GW Pharma (NASDAQ:GWPH) Marijuana Stocks: Constellation Brands (STZ) Source: ShinoStock / Shutterstock.com Constellation Brands is best known as a leading producer and marketer of alcoholic beverages. It holds a large portfolio of beer, wine and distilled spirits brands. Several of those well-recognized brands include Corona, Modelo, Robert Mondavi, Svedka vodka, Casa Noble tequila and High West whiskey. It is one the fastest-growing large consumer packaged goods companies stateside. Outside the U.S., it has operations in Italy, Mexico and New Zealand. The Victor, New York-based group is on our list of marijuana stocks because in 2018, it took a large stake in Ontario, Canada-based Canopy Growth (NYSE:CGC), one of the leading Canadian marijuana producers. STZ’s 38%-stake in CGC means the latter now has considerable managerial and financial backing. So far, this equity stake in Canopy Growth has been an earnings drag for Constellation Brands, and it will likely remain so in the near future. However, any potential improvement in the outlook of the pot sector in Canada and the U.S. could easily benefit STZ stock. Therefore, this indirect play on CGC could be a less risky approach for many investors. Year-to-date, STZ stock is down about 1.5%. However, that metric tells only half the story. Since the lows hit in early spring, the stock is up about 80%. The current forward price-earnings and price-sales ratios stand at at 20.88 and 4.78 respectively. We’d look to buy the the dips in price, especially if there is a decline toward the $175 level. ETFMG Alternative Harvest ETF (MJ) Source: Shutterstock The ETFMG Alternative Harvest ETF offers exposure to Canadian cannabis producers as well as a number of firms with exposure to the industry, albeit indirectly. Thus the fund could be appropriate for long-term investors who are interested in the pot sector, but would like to have access to a diverse range of companies. MJ, which has 37 holdings, tracks the Prime Alternative Harvest index. Canopy Growth, Cronos (NASDAQ:CRON), and Tilray (NASDAQ:TLRY) top the list of holdings. Top-10 names make up around half of net assets, which stand around $550 million. The ETF was launched in 2015. 7 Value Stocks to Buy in an Overvalued Market So far this year, the fund is down more than 30% and hit an all-time low in March. Since 2019, MJ has lost considerable value, driven by the industry’s weakness and poor earnings by most pot companies. These stocks tend to be very choppy when their quarterly earnings are due. Given the volatility in the sector, long-term investors should be ready for large short-term price fluctuations in the fund. The sector is risky, but MJ’s diversification makes it safer than many alternatives. GW Pharma (GWPH) Source: Shutterstock Our final marijuana stock is the cannabis-focused biotech GW Pharma. According to a recent report by the United Nations, Britain is the biggest producer and exporter of legal cannabis in the world. And almost all of the exports are in a single drug, i.e., Sativex, produced by the UK-based GW Pharma. It is used to treat spasms in multiple sclerosis patients. Earlier in the year, the U.S. Drug Enforcement Administration also descheduled Epidiolex, another one of the company’s products. As a result, it is no longer listed as a controlled substance stateside. In August, the U.S. Food and Drug Administration approved it to treat seizures in tuberous sclerosis complex. GW is also one of MJ’s largest holding, accounting for 6.41% of its assets. GWPH stock could be an alternative way to get exposure to the cannabis industry. Year-to-date, the shares are down around 8%. A potential decline toward $90 or below would improve the safety margin for long-term investors. On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article. Tezcan Gecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. She also publishes educational articles on long-term investing. More From InvestorPlace Forget The Election… Pick These Stocks for the Win in 2021 Why Everyone Is Investing in 5G All WRONG America’s #1 Stock Picker Reveals His Next 1,000% Winner Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company The post 3 Marijuana Stocks to Buy With Decriminalization on the Table appeared first on InvestorPlace.